Daclatasvir is
indicated for use, with sofosbuvir, with or without ribavirin for the treatment
of patients with chronic HCV genotype 1 or 3. The use of ribavirin depends on
the patient population treated as outlined below. For patients with HCV/HIV-1
coinfection, the dosage and duration are the same as listed below.
